Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
56 hedge funds and large institutions have $99.1M invested in Cidara Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 16 closing their positions.
81% more capital invested
Capital invested by funds: $54.8M → $99.1M (+$44.3M)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.06% more ownership
Funds ownership: 3.3% → 3.36% (+0.06%)
7% less funds holding
Funds holding: 60 → 56 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.11M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.66M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$5.02M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.15M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.42M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$895K |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$156K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$147K |
CDTX Hedge Fund Activity: Q2 2018 in Review
56 of the 4,371 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2018, worth a combined $99.1M — up 81% from $54.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CDTX and 12 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $9.11M. The largest seller was Broadfin Capital, exiting entirely with an estimated $1.5M sold.
- 56 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2018, down from 60 in Q1 2018.
- Funds reported $99.1M of Cidara Therapeutics stock for Q2 2018, up 81% quarter-over-quarter.
- 12 funds opened new Cidara Therapeutics positions in Q2 2018 and 16 closed out, a net change of -4 holders.
- The largest Cidara Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $9.11M added.
- The largest Cidara Therapeutics seller in Q2 2018 was Broadfin Capital, an estimated $1.5M sold.
Based on aggregated 13F filings for Q2 2018.